NasdaqGS:OLMABiotechs
Did Olema’s (OLMA) Catalyst Watch Listing and Cash Raise Just Reframe Its Investment Narrative?
In recent months, analysts at major banks including Citigroup and UBS have reiterated positive ratings on Olema Pharmaceuticals, citing confidence in its clinical-stage pipeline and strengthened balance sheet following a roughly US$218.5 million public offering in November 2025.
An interesting angle for investors is Olema’s inclusion on Citigroup’s 90-day catalyst watchlist, highlighting expectations around upcoming clinical and corporate milestones.
Next, we’ll examine how Olema’s addition...